Oncolytics Biotech Establishes New At-The-Market Facility; 4Q Loss Widens
Oncolytics Biotech Establishes New At-The-Market Facility; 4Q Loss Widens
DJ Oncolytics Biotech Establishes New At-The-Market Facility; 4Q Loss Widens
By Michael Dabaie
Oncolytics Biotech Inc. said it entered an at-the-market equity offering sales agreement with Canaccord Genuity LLC.
The agreement allows the company to issue common shares from treasury at prevailing market prices, with an aggregate gross sales amount of up to $80 million.
Oncolytics said the ATM facility provides it the option to tap into the financial markets as needed to support business development activities and clinical trials.
Oncolytics reported a net loss for the fourth quarter of C$9.3 million ($7.4 million), compared with a net loss of C$19.4 million in the fourth quarter of 2019. The loss per share was C$0.21 from C$0.71 in the prior-year period.
As of March 4, the company had about C$50 million in cash and cash equivalents.
The company said it is on track to report clinical biomarker and safety data in breast cancer this year.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
March 05, 2021 08:17 ET (13:17 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
DJ Oncolytics Biotech Establishes New At-The-Market Facility; 4Q Loss Widens
DJ腫瘤學生物技術公司建立新的市場設施；第四季度虧損擴大
By Michael Dabaie
邁克爾·達拜(Michael Dabaie)著
Oncolytics Biotech Inc. said it entered an at-the-market equity offering sales agreement with Canaccord Genuity LLC.
Oncolytics Biotech Inc.説，它與Canaccel Genuity LLC達成了一項在市場上進行股權發行的銷售協議。
The agreement allows the company to issue common shares from treasury at prevailing market prices, with an aggregate gross sales amount of up to $80 million.
該協議允許該公司以現行市場價格從國庫發行普通股，總銷售額高達8000萬美元。
Oncolytics said the ATM facility provides it the option to tap into the financial markets as needed to support business development activities and clinical trials.
Oncolytics表示，自動取款機設施為其提供了根據需要進入金融市場的選擇，以支持業務開發活動和臨牀試驗。
Oncolytics reported a net loss for the fourth quarter of C$9.3 million ($7.4 million), compared with a net loss of C$19.4 million in the fourth quarter of 2019. The loss per share was C$0.21 from C$0.71 in the prior-year period.
Oncolytics報告第四季度淨虧損930萬加元(合740萬美元)，而2019年第四季度淨虧損1940萬加元。每股虧損0.21加元，上年同期為0.71加元。
As of March 4, the company had about C$50 million in cash and cash equivalents.
截至3月4日，該公司擁有約5,000萬加元的現金和現金等價物。
The company said it is on track to report clinical biomarker and safety data in breast cancer this year.
該公司表示，今年將報告乳腺癌的臨牀生物標記物和安全性數據。
Write to Michael Dabaie at michael.dabaie@wsj.com
寫信給Michael Dabaie，電子郵件：michael.dabaie@wsj.com
(END) Dow Jones Newswires
(完)道瓊通訊社
March 05, 2021 08:17 ET (13:17 GMT)
2021年3月5日08：17美國東部時間(格林尼治標準時間13：17)
Copyright (c) 2021 Dow Jones & Company, Inc.
版權所有(C)2021年道瓊斯公司
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧